Ocugen, Inc.
OCGN$279M
Micro CapNASDAQBiological Products, (No Diagnostic Substances)🇺🇸North AmericaMALVERN
Drugs in Pipeline
4
Phase 3 Programs
2
Upcoming Catalysts
3
Next Catalyst
Aug 7, 2026
6wMarket Overview
Stock performance and key metrics
OCGN News
Catalyst Timeline
3 upcoming, 0 past
Drug Pipeline
Brimonidine Tartrate
Dry Eye
OCU410ST
Stargardt Disease
OCU400 Low Dose
Retinitis Pigmentosa
Brimonidine
Dry Eye
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Brimonidine Tartrate | Phase 3 | Dry Eye | - | - |
OCU410ST | Phase 3 | Stargardt Disease | - | - |
OCU400 Low Dose | Phase 2 | Retinitis Pigmentosa | - | - |
Brimonidine | Phase 2 | Dry Eye | - | - |
Catalyst Verdict
Market-Implied Move
Regulatory Approvals
Get Catalyst Alerts
Receive weekly digests of upcoming catalysts
Data is aggregated from public sources (FDA, SEC, ClinicalTrials.gov). While we strive for accuracy, information may be incomplete, delayed, or contain errors. Terms apply